Astellas Pharma Yönetim

Yönetim kriter kontrolleri 4/4

Astellas Pharma CEO'su Naoki Okamura, Apr2023 tarihinde atandı, in görev süresi 3.17 yıldır. in toplam yıllık tazminatı ¥ 733.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 19.9% maaş ve 80.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.004% ine doğrudan sahiptir ve bu hisseler $ 943.68K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 3 yıldır.

Anahtar bilgiler

Naoki Okamura

İcra Kurulu Başkanı

JP¥733.0m

Toplam tazminat

CEO maaş yüzdesi	19.92%
CEO görev süresi	3.2yrs
CEO sahipliği	0.004%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Naoki Okamura'un ücretlendirmesi Astellas Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	JP¥733m	JP¥146m	JP¥292b
Dec 31 2025	n/a	n/a	JP¥294b
Sep 30 2025	n/a	n/a	JP¥125b
Jun 30 2025	n/a	n/a	JP¥82b
Mar 31 2025	JP¥664m	JP¥144m	JP¥51b
Dec 31 2024	n/a	n/a	-JP¥57b
Sep 30 2024	n/a	n/a	JP¥55b
Jun 30 2024	n/a	n/a	JP¥22b
Mar 31 2024	JP¥461m	JP¥136m	JP¥17b
Dec 31 2023	n/a	n/a	JP¥4b
Sep 30 2023	n/a	n/a	JP¥38b
Jun 30 2023	n/a	n/a	JP¥107b
Mar 31 2023	JP¥204m	JP¥70m	JP¥99b
Dec 31 2022	n/a	n/a	JP¥136b
Sep 30 2022	n/a	n/a	JP¥149b
Jun 30 2022	n/a	n/a	JP¥118b
Mar 31 2022	n/a	n/a	JP¥124b
Dec 31 2021	n/a	n/a	JP¥120b
Sep 30 2021	n/a	n/a	JP¥119b
Jun 30 2021	n/a	n/a	JP¥101b
Mar 31 2021	JP¥236m	JP¥70m	JP¥121b
Dec 31 2020	n/a	n/a	JP¥138b
Sep 30 2020	n/a	n/a	JP¥140b
Jun 30 2020	n/a	n/a	JP¥187b
Mar 31 2020	JP¥232m	JP¥53m	JP¥195b

Tazminat ve Piyasa: Naoki 'nin toplam tazminatı ($USD 4.54M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 14.67M ).

Tazminat ve Kazançlar: Naoki 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Naoki Okamura (64 yo)

3.2yrs

Görev süresi

JP¥664,000,000

Tazminat

Mr. Naoki Okamura, BSc, served as Chief Business Officer at Astellas Pharma Inc. since September 2021 until 2022. He served as Executive Vice President at Astellas Pharma Inc. since 2021 until April 1, 202...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Naoki Okamura	President	3.2yrs	JP¥664.00m	0.0040% $ 943.7k
Katsuyoshi Sugita	Executive VP	5.1yrs	JP¥295.00m	0.00061% $ 145.4k
Atsushi Kitamura	Senior Executive Officer & CFO	3.4yrs	Veri yok	Veri yok
Nobue Yasuda	General Manager of Finance & Accounting Department	no data	Veri yok	Veri yok
Yoshitsugu Shitaka	Chief Scientific Officer & Senior Managing Executive Officer	5.4yrs	Veri yok	Veri yok
Nobuko Kato	Chief Communications & Investor Relations Officer	no data	Veri yok	Veri yok
Tatjana Dragovic	General Counsel	1.2yrs	Veri yok	Veri yok
Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	10yrs	Veri yok	Veri yok
Jun Kono	Senior Executive Officer & Head of Japan Commercial	2.4yrs	Veri yok	Veri yok
Leticia Delgado-Herrera	VP and Rx+ M&D Head	7.4yrs	Veri yok	Veri yok
Nori Kuwahara	Senior Vice President of Planning & Administration	no data	Veri yok	Veri yok
Salim Mujais	Senior VP & TA Head of Medical Specialties	no data	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: ALPM.Y 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Naoki Okamura	President	7yrs	JP¥664.00m	0.0040% $ 943.7k
Katsuyoshi Sugita	Executive VP	3yrs	JP¥295.00m	0.00061% $ 145.4k
Mark Enyedy	Independent Outside Director	1yr	Veri yok	Veri yok
Takashi Tanaka	Independent Outside Director	5yrs	Veri yok	Veri yok
Masahiro Miyazaki	Outside Independent Director	3yrs	Veri yok	0.00028% $ 66.7k
Kenji Yasukawa	Chairman of the Board	9yrs	JP¥526.00m	0.012% $ 2.9m
Tomoko Aramaki	Outside Independent Director	2yrs	Veri yok	Veri yok
Eriko Sakurai	Independent Outside Director	4yrs	Veri yok	Veri yok
Mika Nakayama	Independent Outside Director	4yrs	Veri yok	Veri yok
Rie Akiyama	Outside Independent Director	3yrs	Veri yok	Veri yok
Yoichi Ohno	Outside Independent Director	3yrs	Veri yok	Veri yok
Rika Hirota	Director	2yrs	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALPM.Y 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/20 21:45
Gün Sonu Hisse Fiyatı	2026/06/18 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2026/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Astellas Pharma Inc. 24 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Astellas Pharma Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Astellas Pharma Inc. Announces Resignation of Andreas Busch, an Outside Director from His Position as Director Effective May 29, 2026

Astellas Pharma Inc., Annual General Meeting, Jun 19, 2026

Astellas Pharma Inc. Announces Resignation of Nick Eshkenazi, Current Chief Digital & Transformation Officer, Effective September 30, 2025

Astellas Pharma Inc., Annual General Meeting, Jun 19, 2025

Astellas Pharma Inc. Announces Management Changes, Effective April 1, 2025

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

Recent updates

Astellas Pharma Inc. Announces Resignation of Andreas Busch, an Outside Director from His Position as Director Effective May 29, 2026

Astellas Pharma Inc. Presents Data on Long-Term Outcomes and Clinical Use of its Oncology Portfolio at ASCO

Astellas Pharma Inc., Annual General Meeting, Jun 19, 2026

Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder Cancer

Astellas Pharma Inc. to Report Fiscal Year 2026 Results on Apr 27, 2026

Astellas Pharma Inc. and Hovon Foundation Confirm Phase 3 Study Results for Xospata (Gilteritinib) in Newly Diagnosed FLT3m+ AML

Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical Trial

Astellas Pharma Inc. Reaches Settlement Agreements with Lupin and Zydus in Myrbetriq Patent Litigation

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2026

Astellas Pharma Inc. to Report Q3, 2026 Results on Feb 04, 2026

Astellas Pharma Inc. and Pfizer Inc. Announces Positive Topline Results from an Interim Analysis of the Phase 3 EV-304 Clinical Trial

U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2026

Astellas Pharma Inc. Presents Preliminary Real-World Veozah (Fezolinetant) Data from Option-Vms Phase Iv Observational Study

Astellas Pharma Inc. Announces First Results from the Open-Label Extension Trial of the Phase 3 GATHER2 Study

Astellas Pharma Inc. Confirms Phase 2 GLEAM Trial Did Not Meet Primary Endpoint of Overall Survival in Patients with Metastatic Pancreatic Cancer

Astellas Pharma Inc. to Report Q2, 2026 Results on Oct 30, 2025

Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer Is Now Funded in Both Ontario and Quebec

Astellas Pharma Inc. to Present Pioneering Advances Across Its Portfolio and Pipeline At Esmo 2025

Astellas Pharma Inc. Announces Resignation of Nick Eshkenazi, Current Chief Digital & Transformation Officer, Effective September 30, 2025

Astellas Pharma Inc. Announces Japanese Ministry of Health, Labor and Welfare Grants Conditional Approval of IZERVAY for Suppression of Geographic Atrophy Growth in Atrophic Age-Related Macular Degeneration

PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

Astellas Pharma Inc. to Report Q1, 2026 Results on Jul 30, 2025

Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDI

Astellas Pharma Canada, Inc. Announces That XTANDI®? (enzalutamide) Now Funded in Ontario for All Approved Prostate Cancer Indications

Astellas Pharma Inc. and Pfizer Inc. Announces Long-Term Overall Survival in Metastatic Hormone-S sensitive Prostate Cancer

Astellas Pharma Inc. Presents New Data That Explores Potential of Its Cancer Therapies At 2025 Asco Annual Meeting

Astellas engages with Farallon

Astellas Pharma Inc., Annual General Meeting, Jun 19, 2025

Astellas Pharma Inc. to Report Fiscal Year 2025 Results on Apr 25, 2025

U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan

Astellas Pharma Inc. Announces Management Changes, Effective April 1, 2025

Astellas Receives Health Canada Approval for Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. Announces China's National Medical Products Administration (Nmpa) Approves Padcev™ in Combination with Keytruda® (Pembrolizumab) for the Treatment of Advanced Bladder Cancer

China's National Medical Products Administration Approves Vyloy (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Astellas Pharma Inc. to Report Q3, 2025 Results on Feb 04, 2025

Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy

Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S

Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024

Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy